The invention provides a method of treating or preventing heart failure or a disease or condition associated with heart failure comprising administering an effective dose of an apelin peptide or APJ receptor ligand to the subject.
Stanford researchers have developed a method for estimating the risk for disease on a genome-wide scale while incorporating population and familial haplotype phasing.